

THE IMPACT OF ANTIBODY-DRUG CONJUGATES (ADCs) IN THE CHANGING TREATMENT LANDSCAPE OF ADVANCED NSCLC

Chairs

Enriqueta Felip, Barcelona, Spain

Pasi A. Jänne, Boston, MA, USA

SUNDAY, 22 OCTOBER 2023

13:00 - 14:30 CEST, HALL 3 - TOLEDO AUDITORIUM

13:00	Welcome and introduction	Enriqueta Felip, Barcelona, Spain
13:10	Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients	Pasi A. Jänne, Boston, MA, USA
13:30	Improving the safety profiles of ADCs: Early detection and optimal management of toxicities	Maurice Pérol, Lyon, France
13:50	ADCs: Novel combinations with precision therapeutics and the quest for biomarkers	Anne-Marie C. Dingemans, Rotterdam, Netherlands
14:10	Q&A and discussion	All speakers
14:25	Concluding remarks	Pasi A. Jänne, Boston, MA, USA

This educational activity is provided by ESMO and supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca.

